Zacks Investment Research cut shares of Natera (NASDAQ:NTRA) from a hold rating to a sell rating in a research report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

Other research analysts also recently issued reports about the stock. ValuEngine downgraded shares of Natera from a strong-buy rating to a buy rating in a research note on Wednesday, January 9th. Canaccord Genuity restated a buy rating and issued a $25.00 target price on shares of Natera in a research note on Monday, March 11th. Finally, BidaskClub upgraded shares of Natera from a sell rating to a hold rating in a research note on Monday, March 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Natera has a consensus rating of Buy and an average target price of $27.75.

Natera stock opened at $20.83 on Wednesday. Natera has a 52-week low of $9.15 and a 52-week high of $29.62. The firm has a market capitalization of $1.31 billion, a PE ratio of -9.69 and a beta of 1.89. The company has a quick ratio of 1.99, a current ratio of 2.11 and a debt-to-equity ratio of 2.28.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, March 12th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.51). Natera had a negative net margin of 49.72% and a negative return on equity of 790.13%. The company had revenue of $67.00 million during the quarter, compared to analyst estimates of $62.87 million. Research analysts anticipate that Natera will post -2.24 EPS for the current fiscal year.

In other Natera news, insider Jonathan Sheena sold 2,620 shares of the stock in a transaction on Friday, March 29th. The shares were sold at an average price of $20.50, for a total transaction of $53,710.00. Following the transaction, the insider now directly owns 240,390 shares in the company, valued at approximately $4,927,995. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Burkes Brophy sold 3,192 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $16.00, for a total transaction of $51,072.00. Following the transaction, the chief financial officer now owns 13,422 shares in the company, valued at $214,752. The disclosure for this sale can be found here. Insiders sold 350,699 shares of company stock valued at $7,120,439 over the last 90 days. Insiders own 13.18% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of NTRA. FMR LLC bought a new position in Natera during the 3rd quarter valued at $59,599,000. Vanguard Group Inc boosted its stake in Natera by 28.9% during the 3rd quarter. Vanguard Group Inc now owns 3,612,860 shares of the medical research company’s stock valued at $86,493,000 after acquiring an additional 808,976 shares during the last quarter. Vanguard Group Inc. boosted its stake in Natera by 28.9% during the 3rd quarter. Vanguard Group Inc. now owns 3,612,860 shares of the medical research company’s stock valued at $86,493,000 after acquiring an additional 808,976 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Natera by 92.9% during the 3rd quarter. Renaissance Technologies LLC now owns 1,528,400 shares of the medical research company’s stock valued at $36,590,000 after acquiring an additional 736,000 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in Natera by 33.5% during the 3rd quarter. BlackRock Inc. now owns 2,785,208 shares of the medical research company’s stock valued at $66,679,000 after acquiring an additional 698,379 shares during the last quarter. Hedge funds and other institutional investors own 88.22% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Earnings Reports

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.